FinTrust Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

FinTrust Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,561	Closed	-$83K	–	1256
2022 Q3	$83K	Hold	1,561	–	–	0.02%	410
2022 Q2	$91K	Sell	1,561 -757	-33%	-$49.6K	0.02%	413
2022 Q1	$176K	Buy	2,318 +1,925	+490%	+$128K	0.04%	307
2021 Q4	$24K	Hold	393	–	–	0.01%	698
2021 Q3	$22K	Sell	393 -500	-56%	-$28.8K	0.01%	726
2021 Q2	$54K	Sell	893 -3,200	-78%	-$203K	0.01%	544
2021 Q1	$287K	Buy	4,093 +3,578	+695%	+$256K	0.08%	209
2020 Q4	$31K	Sell	515 -160	-24%	-$9.37K	0.01%	575
2020 Q3	$41	Sell	675 -812	-55%	-$47.2K	0.01%	531
2020 Q2	$78K	Buy	1,487 +752	+102%	+$31.4K	0.03%	388
2020 Q1	$25K	Hold	735	–	–	0.01%	581
2019 Q4	$33K	Hold	735	–	–	0.01%	526
2019 Q3	$28K	Buy	735 +124	+20%	+$4.95K	0.01%	574
2019 Q2	$27K	Hold	611	–	–	0.01%	538
2019 Q1	$23K	Buy	+611	New	+$23.8K	0.01%	570

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

FinTrust Capital Advisors's PCRX Position: Q4 2022 in Review

FinTrust Capital Advisors sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 1,561 shares — an estimated $83K sold.

FinTrust Capital Advisors first reported a position in PCRX in Q1 2019 and held it in 15 quarters. The position peaked at $287K in Q1 2021. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

FinTrust Capital Advisors reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
FinTrust Capital Advisors sold 1,561 Pacira BioSciences shares in Q4 2022, an estimated $83K.
FinTrust Capital Advisors first reported a position in Pacira BioSciences in Q1 2019 and held it in 15 quarters.
FinTrust Capital Advisors's Pacira BioSciences position peaked at $287K in Q1 2021.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on FinTrust Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.